PTC Therapeutics (PTCT) EVP trades options and sells 2,265 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
PTC Therapeutics executive Mark Elliott Boulding exercised stock options and sold shares in a pre-planned trade. He exercised options to acquire 2,265 shares of Common Stock at an exercise price of $39.42 per share and received 2,265 shares.
On the same date, he sold 822 shares at a weighted average price of $68.91 per share and 1,443 shares at a weighted average price of $69.75 per share, pursuant to a Rule 10b5-1 trading plan. After these transactions, he directly holds 105,212 shares of PTC Therapeutics Common Stock.
Positive
- None.
Negative
- None.
Insights
Routine option exercise paired with pre-planned sales; modest net reduction in holdings.
Executive vice president and CLO Mark Elliott Boulding exercised options for 2,265 shares at an exercise price of $39.42 and sold the same number of shares in two open-market transactions around $69 per share. This pattern is typical of monetizing vested equity.
The filing notes the trades were made under a written Rule 10b5-1 plan adopted on September 10, 2025, indicating they were pre-scheduled rather than opportunistic. Following the exercise-and-sell sequence, he retains 105,212 shares of Common Stock directly, suggesting these transactions represent a limited portion of his overall equity position.
Insider Trade Summary 10b5-1
Net Seller: 2,265 shares ($157,293)
Net Sell
4 txns
Insider
Boulding Mark Elliott
Role
EXEC. VP AND CLO
Sold
2,265 shs ($157K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 2,265 | $0.00 | -- |
| Exercise | Common Stock | 2,265 | $39.42 | $89K |
| Sale | Common Stock | 822 | $68.91 | $57K |
| Sale | Common Stock | 1,443 | $69.75 | $101K |
Holdings After Transaction:
Stock Option (Right to Buy) — 6,798 shares (Direct);
Common Stock — 107,477 shares (Direct)
Footnotes (1)
- This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $68.24 to $69.17 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $69.30 to $70.25 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This option was granted on January 5, 2023 and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
Key Figures
Options exercised: 2,265 shares
Option exercise price: $39.42 per share
Shares sold at $68.91: 822 shares
+5 more
8 metrics
Options exercised
2,265 shares
Stock Option (Right to Buy) exercised on 2026-04-06
Option exercise price
$39.42 per share
Exercise price for 2,265 underlying Common shares
Shares sold at $68.91
822 shares
Open-market sale at weighted average price $68.91
Shares sold at $69.75
1,443 shares
Open-market sale at weighted average price $69.75
Net shares transacted
2,265 shares net sold
transactionSummary netBuySellShares
Shares held after transactions
105,212 shares
Total Common Stock directly owned after last sale
Option expiration
January 4, 2033
Expiration date of the exercised stock option
10b5-1 plan adoption date
September 10, 2025
Date written Rule 10b5-1 plan was adopted
Key Terms
Rule 10b5-1 plan, Stock Option (Right to Buy, weighted average price, vests over four years, +1 more
5 terms
Rule 10b5-1 plan financial
"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted..."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
Stock Option (Right to Buy financial
"security_title": "Stock Option (Right to Buy)""
weighted average price financial
"This price represents the weighted average price of sale transactions..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
vests over four years financial
"This option was granted on January 5, 2023 and vests over four years..."
A grant that "vests over four years" is a promise that ownership of awarded company shares or options becomes permanent in small portions over a four-year period instead of all at once. Think of it like earning a four-year subscription one month at a time: the recipient gains the right to a bit more stock as time passes, which matters to investors because it affects when employees can sell shares, how quickly ownership shifts, and the timing of potential dilution or insider selling.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
What insider transactions did PTC Therapeutics (PTCT) report for Mark Elliott Boulding?
PTC Therapeutics reported that executive Mark Elliott Boulding exercised stock options for 2,265 Common shares at $39.42 and sold 2,265 shares in open-market trades around $69. After these transactions, he directly holds 105,212 shares of PTC Therapeutics Common Stock.
Were the recent PTCT insider stock sales by Mark Elliott Boulding pre-planned?
Yes. The filing states the transactions were effected under a written Rule 10b5-1 trading plan adopted on September 10, 2025. Such plans schedule trades in advance, indicating these sales were pre-arranged rather than discretionary responses to short-term market developments.
What stock options did the PTC Therapeutics executive exercise in this Form 4?
He exercised a Stock Option (Right to Buy) covering 2,265 underlying Common shares at an exercise price of $39.42 per share, with the option originally granted on January 5, 2023 and vesting over four years, according to the vesting schedule described in the footnotes.